Seminars in nuclear medicine最新文献_第2页

The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors. [177Lu] Lu-Satoreotide Tetraxetan在生长抑素受体阳性神经内分泌肿瘤中的作用。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-08-11 DOI: 10.1053/j.semnuclmed.2025.07.002

Kalyan Mansukhbhai Shekhda, Shaunak Navalkissoor

{"title":"The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors.","authors":"Kalyan Mansukhbhai Shekhda, Shaunak Navalkissoor","doi":"10.1053/j.semnuclmed.2025.07.002","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.07.002","url":null,"abstract":"<p><p>Peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor with receptor agonists has emerged as a key treatment in the management of well-differentiated neuroendocrine tumors (NETs). The therapeutic efficacy of these agents has traditionally been attributed to receptor-mediated internalization of the radiolabeled peptide into tumor cells. In contrast, somatostatin receptor (SSTR) antagonists bind to the receptor without undergoing significant internalization. Despite this theoretical limitation, accumulating preclinical and clinical evidence supports the therapeutic utility of SSTR antagonists. These agents have been shown to bind to a greater number of receptor sites and exhibit prolonged tumor retention, properties that may enhance both imaging sensitivity and therapeutic efficacy. Among the antagonists studied, [¹⁷⁷Lu]Lu-satoreotide tetraxetan is the most extensively investigated to date. In this article, we review both preclinical and clinical data evaluating the efficacy and safety of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in the treatment of neuroendocrine tumors. We also provide a brief overview of other SSTR antagonists currently under investigation.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter from the Editors 编辑的信

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-29 DOI: 10.1053/j.semnuclmed.2025.07.004

Kirsten Bouchelouche, M. Michael Sathekge

引用次数: 0

New Promising Targets for Imaging in Infection 新的有希望的感染成像靶点。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-22 DOI: 10.1053/j.semnuclmed.2025.06.013

Honest Ndlovu , Ismaheel O. Lawal , Kgomotso M.G. Mokoala , Sipho Mdanda , Mike M. Sathekge

引用次数: 0

PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update 前列腺癌以外的实体肿瘤的psma靶向正电子发射断层成像：最新进展。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-19 DOI: 10.1053/j.semnuclmed.2025.06.006

Nozipho Nyakale , Alex Maes , Mike Sathekge , Shaobo Li , Justine Maes , Christophe Van de Wiele

{"title":"PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update","authors":"Nozipho Nyakale , Alex Maes , Mike Sathekge , Shaobo Li , Justine Maes , Christophe Van de Wiele","doi":"10.1053/j.semnuclmed.2025.06.006","DOIUrl":"10.1053/j.semnuclmed.2025.06.006","url":null,"abstract":"<div><div>Prostate-specific membrane antigen (PSMA) has been previously shown to be over-expressed on newly formed vessels of a wide variety of solid tumors other than prostate carcinoma. Accordingly, the potential role of PSMA-targeted positron emitting tomography for staging, restaging and prediction of response to PSMA-targeted treatment modalities, including <sup>177</sup>Lu-PSMA-617, in other solid tumor types is being explored. Results derived from currently available studies on the role of PSMA-targeted imaging in solid tumors other than prostate carcinoma are encouraging with amongst others evidence of improved diagnostic accuracy in patients suffering from clear cell renal cell carcinoma and adenoid cystic adenocarcinoma of the salivary gland when compared to standard of care imaging, leading to a change in patient management in a significant number of patients. Furthermore, in hepatocellular carcinoma and glioblastoma, the comparable diagnostic accuracy of PSMA-targeted PET imaging when compared to contrast-enhanced CT and MRI suggest a potential use of PSMA-targeted PET when findings derived from morphological imaging are doubtful. Also, high PSMA-targeted PET-ligand uptake has been identified in iodine refractory thyroid carcinoma lesions as well as in triple negative breast carcinoma, suggesting a potential role for PSMA-targeted therapy in these patient populations. Thus far published results warrant, however, confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 672-679"},"PeriodicalIF":5.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence for Tumor [18F]FDG PET Imaging: Advancements and Future Trends - Part II 人工智能在肿瘤中的应用[18F]FDG PET成像：进展和未来趋势-第二部分。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-18 DOI: 10.1053/j.semnuclmed.2025.06.012

Alireza Safarian , Seyed Ali Mirshahvalad , Abolfazl Farbod , Theresa Jung , Hadi Nasrollahi , Gregor Schweighofer-Zwink , Gundula Rendl , Christian Pirich , Reza Vali , Mohsen Beheshti

{"title":"Artificial Intelligence for Tumor [18F]FDG PET Imaging: Advancements and Future Trends - Part II","authors":"Alireza Safarian , Seyed Ali Mirshahvalad , Abolfazl Farbod , Theresa Jung , Hadi Nasrollahi , Gregor Schweighofer-Zwink , Gundula Rendl , Christian Pirich , Reza Vali , Mohsen Beheshti","doi":"10.1053/j.semnuclmed.2025.06.012","DOIUrl":"10.1053/j.semnuclmed.2025.06.012","url":null,"abstract":"<div><div>The integration of artificial intelligence (AI) into [<sup>18</sup>F]FDG PET/CT imaging continues to expand, offering new opportunities for more precise, consistent, and personalized oncologic evaluations. Building on the foundation established in Part I, this second part explores AI-driven innovations across a broader range of malignancies, including hematological, genitourinary, melanoma, and central nervous system tumors as well applications of AI in pediatric oncology.</div><div>Radiomics and machine learning algorithms are being explored for their ability to enhance diagnostic accuracy, reduce interobserver variability, and inform complex clinical decision-making, such as identifying patients with refractory lymphoma, assessing pseudoprogression in melanoma, or predicting brain metastases in extracranial malignancies. Additionally, AI-assisted lesion segmentation, quantitative feature extraction, and heterogeneity analysis are contributing to improved prediction of treatment response and long-term survival outcomes. Despite encouraging results, variability in imaging protocols, segmentation methods, and validation strategies across studies continues to challenge reproducibility and remains a barrier to clinical translation. This review evaluates recent advancements of AI, its current clinical applications, and emphasizes the need for robust standardization and prospective validation to ensure the reproducibility and generalizability of AI tools in PET imaging and clinical practice.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 856-868"},"PeriodicalIF":5.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal Carcinoma FAPI PET显像对HCC、CCC、CUP及腹膜癌的临床影响。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-18 DOI: 10.1053/j.semnuclmed.2025.07.001

Emil Novruzov, Eduards Mamlins, Yuriko Mori, Jens Cardinale, Frederik L. Giesel

引用次数: 0

Radiotracing the Future: Non-FDG Radiotracers Nuclear Medicine 放射性示踪的未来：非fdg放射性示踪剂核医学。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-16 DOI: 10.1053/j.semnuclmed.2025.06.005

Giuseppe Arturo Fuso , Gianfilippo Bianciardi , Riccardo Mei , Irene Brusa , Stefano Emiliani , Emilia Fortunati , Cristina Nanni

{"title":"Radiotracing the Future: Non-FDG Radiotracers Nuclear Medicine","authors":"Giuseppe Arturo Fuso , Gianfilippo Bianciardi , Riccardo Mei , Irene Brusa , Stefano Emiliani , Emilia Fortunati , Cristina Nanni","doi":"10.1053/j.semnuclmed.2025.06.005","DOIUrl":"10.1053/j.semnuclmed.2025.06.005","url":null,"abstract":"<div><div>Positron Emission Tomography/Computed Tomography (PET/CT) is an advanced hybrid imaging modality that synergistically combines metabolic and anatomical data, revolutionizing diagnostic accuracy and therapeutic monitoring in various pathologies. While 18F-fluorodeoxyglucose (FDG) remains the cornerstone radiotracer for many oncologic and nononcologic applications, its limitations—such as nonspecific uptake in inflammation and limited sensitivity in certain tumor subtypes—have catalyzed the development and clinical adoption of non-FDG radiotracers. These novel agents exhibit diverse biological targets, enabling more precise characterization of tissue physiology and pathology. Among them, radiotracers such as 68Ga-DOTA Peptides, 18F-fluciclovine, 68Ga-PSMA, 11C-choline, and 18F-FDOPA have demonstrated utility in neuroendocrine tumors, prostate cancer, gliomas, and parkinsonian syndromes. Their application enhances disease detection, improves staging and restaging accuracy, and supports theranostic strategies. The integration of non-FDG PET tracers in clinical practice requires nuanced understanding of their pharmacokinetics, target specificity, and optimal imaging protocols. Furthermore, these tracers open avenues for personalized medicine, allowing for biomarker-guided management. As evidence continues to evolve, non-FDG PET/CT is poised to become indispensable in precision oncology and targeted molecular imaging across multiple disciplines.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 648-663"},"PeriodicalIF":5.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update FAPI PET/CT在胆管癌和胰腺癌诊断中的价值

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-16 DOI: 10.1053/j.semnuclmed.2025.06.011

Kim M. Pabst , Wolfgang P. Fendler , Leonie S. Jochheim , Ken Herrmann

{"title":"The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update","authors":"Kim M. Pabst , Wolfgang P. Fendler , Leonie S. Jochheim , Ken Herrmann","doi":"10.1053/j.semnuclmed.2025.06.011","DOIUrl":"10.1053/j.semnuclmed.2025.06.011","url":null,"abstract":"<div><div>To date, contrast-enhanced CT (ceCT), magnetic resonance imaging (MRI), and, in selected cases, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) are the current standard imaging modalities for staging of pancreatic cancer and cholangiocarcinoma. Fibroblast activation protein alpha (FAP) has gained interest as a promising molecular imaging target, particularly in tumors with a pronounced desmoplastic reaction such as pancreatic cancer and cholangiocarcinoma. Radiolabeled FAP inhibitors (FAPIs) enable noninvasive visualization of cancer using PET/CT. Recent studies have demonstrated that FAPI PET/CT provides superior sensitivity compared to ceCT and <sup>18</sup>F-FDG PET/CT in cholangiocarcinoma and pancreatic cancer for detecting primary tumors, lymph node involvement, and distant metastases, particularly in hepatic metastases due to low physiological background uptake. Furthermore, FAPI PET/CT has been shown to affect TNM staging and subsequently alter treatment-decision making. Beyond staging, early evidence suggests a prognostic potential of FAPI PET/CT in tumor grading, therapy response assessment, and survival outcomes, although data remain limited. On the other hand, FAPI PET/CT comes with limitations, particularly in the context of fibrotic and inflammatory processes such as liver cirrhosis, pancreatitis, or primary sclerosing cholangitis, which may result in false-positive findings. This review summarizes the current clinical evidence for FAPI PET/CT in pancreatic cancer and cholangiocarcinoma, with a focus on diagnostic performance, prognostic relevance, therapeutic implications, and potential pitfalls.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 701-709"},"PeriodicalIF":5.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucin-Targeted Antibodies for Ovarian Cancer. 用于卵巢癌的黏液蛋白靶向抗体

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-03 DOI: 10.1053/j.semnuclmed.2025.06.007

Shaniqua A Lawson, Jason S Lewis

{"title":"Mucin-Targeted Antibodies for Ovarian Cancer.","authors":"Shaniqua A Lawson, Jason S Lewis","doi":"10.1053/j.semnuclmed.2025.06.007","DOIUrl":"10.1053/j.semnuclmed.2025.06.007","url":null,"abstract":"<p><p>Ovarian cancer remains a leading cause of gynecologic cancer mortality, driven in part by late-stage diagnoses and high recurrence rates. Among emerging molecular targets, mucins-highly glycosylated transmembrane glycoproteins overexpressed and aberrantly glycosylated in epithelial ovarian cancers-have garnered increasing interest for both imaging and therapeutic strategies. This review highlights the expression profiles and clinical implications of key mucins (MUC1, MUC16) and evaluates antibody-based modalities that leverage these targets for enhanced tumor detection and treatment. We discuss the current landscape of therapeutic strategies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and radioimmunotherapy, with emphasis on recent preclinical and clinical advances. We also examine the role of mucin-targeted antibodies in imaging and the integration of theranostic platforms. Key challenges such as antigen heterogeneity, immunogenicity, and tumor penetration are addressed, along with future directions for optimizing mucin-directed therapies. Together, these efforts underscore the ever-expanding potential of mucin-targeted immunotherapy to improve outcomes for patients with ovarian cancer.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[¹⁷⁷Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review. [177]卢- fapi放射治疗在实体瘤中的应用前景。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-07-03 DOI: 10.1053/j.semnuclmed.2025.06.010

Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Saad Ruzzeh, Marwah Abdulrahman, Serin Moghrabi, Rawa Ahmed, Hongcheng Shi, Fadi Khreish, Michael C Kreissl, Rula Amarin, Kamal Al-Rabi, Asem Mansour, Hikmat Abdel-Razeq

{"title":"[<sup>177</sup>Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review.","authors":"Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Saad Ruzzeh, Marwah Abdulrahman, Serin Moghrabi, Rawa Ahmed, Hongcheng Shi, Fadi Khreish, Michael C Kreissl, Rula Amarin, Kamal Al-Rabi, Asem Mansour, Hikmat Abdel-Razeq","doi":"10.1053/j.semnuclmed.2025.06.010","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.06.010","url":null,"abstract":"<p><p>[<sup>177</sup>Lu]Lu-FAPI, a novel and innovative radioligand targeting fibroblast activation protein (FAP), has rapidly emerged as a powerful therapeutic strategy for difficult-to-treat solid malignancies. FAP is highly expressed in cancer-associated fibroblasts (CAFs) across a broad spectrum of solid malignancies, thereby providing a valuable therapeutic target for novel radiopharmaceuticals. To date, a growing body of preliminary studies has explored the therapeutic potential of [<sup>177</sup>Lu]Lu-FAPI in oncology, with numerous ongoing clinical trials currently recruiting patients to substantiate its evolving prospects. This comprehensive review critically synthesizes current clinical evidence on [<sup>177</sup>Lu]Lu-FAPI radioligand therapy (RLT), outlining its available formulations, therapeutic efficacy, safety profile, recent advancements, challenges, and emerging applications across diverse tumor types. [<sup>177</sup>Lu]Lu-FAPI has shown considerable promise as an effective and relatively safe theranostic agent, with particular advantages in combination therapy approaches. Nevertheless, larger, well-controlled clinical studies are essential to establish its long-term efficacy and safety profile. Despite current limitations, this review underscores the emerging role of [<sup>177</sup>Lu]Lu-FAPI in oncological care, with growing relevance to personalized oncology strategies, and calls for further investigation to refine its clinical integration and maximize patient-specific outcomes.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0